Elbasvir - Latest Advances

Rational design and relative bioperformance of high drug load grazoprevir amorphous nanoparticle formulations.

Journal: Pharmaceutical development and technology

Published: August 07, 2025

Molecular chameleons adaptability in target binding.

Journal: Structural dynamics (Melville, N.Y.)

Published: April 04, 2025

Targeting Telomere Shelterin Protein TPP1 with Elbasvir: Induction of Autophagy and Suppression of Esophageal Cancer Tumorigenesis.

Journal: Anti-cancer agents in medicinal chemistry

Published: March 16, 2025

Development of a chemically induced dissociation system via phage surface-displayed nanobody screening.

Journal: FEBS letters

Published: February 14, 2025

Structural insight into the conversion of DhNik1, a hybrid histidine kinase from Debaryomyces hansenii to a cytotoxic phosphatase conformation for novel antifungal agent.

Journal: Journal of molecular biology

Published: January 07, 2025

Potential Inhibitors of SARS-CoV-2 Developed through Machine Learning, Molecular Docking, and MD Simulation.

Journal: Medicinal chemistry (Shariqah (United Arab Emirates))

Published: December 26, 2024

In silico screening of potential FGF2 inhibitors for cancer therapy.

Journal: In silico pharmacology

Published: December 10, 2024

Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries.

Journal: BMJ open gastroenterology

Published: November 07, 2024

Figure 1: Treatment of hepatitis C virus infection in treatment-naive adults.

Journal: The Medical letter on drugs and therapeutics

Published: October 28, 2024

Table 3: Some drug interactions with DAAs for HCV infection.

Journal: The Medical letter on drugs and therapeutics

Published: October 28, 2024

Drugs for hepatitis C virus infection.

Journal: The Medical letter on drugs and therapeutics

Published: October 28, 2024

Elucidating Contributions of Drug Transporters/Enzyme to Nonlinear Pharmacokinetics of Grazoprevir by PBPK Modeling With a Cluster Gauss-Newton Method.

Journal: CPT: pharmacometrics & systems pharmacology

Published: October 04, 2024

Filters

Rational design and relative bioperformance of high drug load grazoprevir amorphous nanoparticle formulations.

Rational design and relative bioperformance of high drug load grazoprevir amorphous nanoparticle formulations.

Molecular chameleons adaptability in target binding.

Molecular chameleons adaptability in target binding.

Targeting Telomere Shelterin Protein TPP1 with Elbasvir: Induction of Autophagy and Suppression of Esophageal Cancer Tumorigenesis.

Targeting Telomere Shelterin Protein TPP1 with Elbasvir: Induction of Autophagy and Suppression of Esophageal Cancer Tumorigenesis.

Development of a chemically induced dissociation system via phage surface-displayed nanobody screening.

Development of a chemically induced dissociation system via phage surface-displayed nanobody screening.

Structural insight into the conversion of DhNik1, a hybrid histidine kinase from Debaryomyces hansenii to a cytotoxic phosphatase conformation for novel antifungal agent.

Structural insight into the conversion of DhNik1, a hybrid histidine kinase from Debaryomyces hansenii to a cytotoxic phosphatase conformation for novel antifungal agent.

Potential Inhibitors of SARS-CoV-2 Developed through Machine Learning, Molecular Docking, and MD Simulation.

Potential Inhibitors of SARS-CoV-2 Developed through Machine Learning, Molecular Docking, and MD Simulation.

In silico screening of potential FGF2 inhibitors for cancer therapy.

In silico screening of potential FGF2 inhibitors for cancer therapy.

Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries.

Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries.

Figure 1: Treatment of hepatitis C virus infection in treatment-naive adults.

Figure 1: Treatment of hepatitis C virus infection in treatment-naive adults.

Table 3: Some drug interactions with DAAs for HCV infection.

Table 3: Some drug interactions with DAAs for HCV infection.

Drugs for hepatitis C virus infection.

Drugs for hepatitis C virus infection.

Elucidating Contributions of Drug Transporters/Enzyme to Nonlinear Pharmacokinetics of Grazoprevir by PBPK Modeling With a Cluster Gauss-Newton Method.

Elucidating Contributions of Drug Transporters/Enzyme to Nonlinear Pharmacokinetics of Grazoprevir by PBPK Modeling With a Cluster Gauss-Newton Method.